TABLE 6.
Frequency distributions of PFA IC50s for recent clinical isolates using the ACTG consensus protocol
| PFA IC50 (μM) | No. of assays with IC50 at each PFA concn
|
|||||
|---|---|---|---|---|---|---|
| CMV 1a | CMV 2 | CMV 3 | CMV 4 | CMV 5 | CMV 6 | |
| <25 | 2 | |||||
| >25–50 | 1 | 2 | 1 | |||
| >50–100 | 1 | 1 | 1 | 3 | ||
| >100–200 | 2 | 2 | 1 | 4 | 6 | 3 |
| >200–400 | 4 | 4 | 2 | 4 | 1 | 5 |
| >400–800 | 2 | 1 | 2 | 1 | ||
| >800–1,600 | 2 | 1 | 2 | |||
| >1,600 | 4 | 1 | ||||
| Total no. of assays | 10b | 10b | 11c | 12 | 12 | 11c |
| Median IC50 | 227.65 | 200.14 | 855.85 | 184.84 | 117.19 | 325.18 |
| No. (%) resistant | 2 (20) | 1 (10) | 8 (73) | 1 (8) | 1 (8) | 3 (27) |
a
CMV 1 to 6 were not plaque purified.
b
Data not submitted by two laboratories.
c
IC50 could not be determined for one data set due to inconsistent results.